drugset / Trial / NCT02437461

Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis

NCT02437461 ↗

Phase 4 Unknown 159 enrolled Uppsala University
RandomizedParallel-groupSingle-blindTreatment

Summary

This prospective randomised controlled single blind trial comparing the relapse rate in 6 months for 20 mg versus 40 mg intraarticular triamcinolone hexacetonide (Lederspan®) for knee synovitis in patients with rheumatoid arthritis (RA) and psoriatic artritis (PsoA) is performed to find the optimal dose to use.

Timeline

Start
2015-04
Primary completion
2017-09-30
Completion
2018-06-20

Outcome

Missed primary endpoint

paper The proportion of relapse after 6 months was equal in the 20 mg and 40 mg THA treatment arms (30% vs 32%, respectively, p = 0.822) PMID 30843453 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Triamcinolone Hexacetonide Other / unclassified 20 mg Other
Subject Triamcinolone Hexacetonide Other / unclassified 40 mg Other

Indications